Abstract:Elevated levels of vascular endothelial growth factor (VEGF) contribute to angiogenesis and serous cavity effusions. The present study evaluated the diagnostic and prognostic values of VEGF-A, -C and -D proteins in the serum, supernatant fluid and exfoliated cells of cancer patients with malignant effusions compared with patients with benign effusions. An enzyme-linked immunosorbent assay was used to detect levels of VEGF-A, -C and -D proteins in the sera of 79 cases (30 lung cancer, 21 gastric cancer and 28 benign effusions) and the supernatant fluid of 96 cases (38 lung cancer, 30 gastric cancer, and 28 benign effusion). Immunocytochemistry detected the expression of VEGF-A, -C and -D proteins in effusion cells from 71 cases (34 lung cancer, 17 gastric cancer and 20 benign effusions). The data were further investigated to determine whether there was an association between VEGF subtype expression and clinicopathological characteristics and prognosis. The expression levels of VEGF-A in the supernatant fluid were increased in the lung and gastric cancer patient samples compared with the benign effusions (P<0.05). The VEGF-A level in the supernatant fluid was significantly increased compared with the corresponding sera of patients with malignant effusion (P<0.05). VEGF-A, -C and -D proteins in the exfoliated cells from primary lung or gastric cancer effusions were expressed at 52.94, 70.58 and 82.35%, respectively, whereas their expression was not detected in the exfoliated cells from benign effusion, with the exception of mesothelial cells. The levels of VEGF-A and VEGF-C in the supernatant fluid levels and the cell levels of VEGF-A were inversely associated with age; in addition, VEGF-A levels in the supernatant fluid were associated with malignant and bloody effusion, and only cavity metastasis (P<0.05). Survival analysis demonstrated a relatively reduced survival time for patients with VEGF-A levels of >406.19 pg/ml in the supernatant fluid compared with patients with VEGF-A levels of ≤406.19 pg/ml (P=0.066). Serum VEGF-A, -C and -D levels exhibited no evident clinical significance in the diagnosis and prognosis of serous cavity effusions. VEGF-A in the supernatant fluid merits further study as a tumor marker in the clinical setting to discriminate benign from malignant effusions, while cellular VEGF-C and -D may contribute to the formation of malignant effusions.

Diagnostic efficacy of serum vascular endothelial growth factor -D in diffuse cystic lung disease.

[Value of Serum-Vascular Endothelial Growth Factor in the Differential Diagnosis of Solitary Pulmonary Nodule].

Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis

Diagnostic value of serum vascular endothelial growth factor-D in Korean patients with lymphangioleiomyomatosis

Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis

Use of Quantitative CT Analysis to Evaluate the Degree of Lung Destruction in Lymphangioleiomyomatosis

Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Could Detection Of Vegf In Exhaled Breath Condensate Be More Helpful For Non-Small Cell Lung Cancer?

Preliminary Study of VEGF and Its Receptor Expression on Childhood Acute Lymphoblastic Leukemia and Its Relativity to Clinical Manifestations

Using Semi-Automated CT Analysis to Determine Cyst Burden in Diffuse Cystic Lung Diseases

Dynamic Contrast-Enhanced Computed Tomography Functional Imaging for the Evaluation of Tumor Angiogenesis in Patients with Lung Carcinoma

Differential Expression of Vascular Endothelial Growth Factor-A, -C and -D for the Diagnosis and Prognosis of Cancer Patients with Malignant Effusions.

The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic

Clinical Value of Vascular Endothelial Growth Factor Combined with Interferon-Γ in Diagnosing Malignant Pleural Effusion and Tuberculous Pleural Effusion

Vascular Endothelial Growth Factor in the Serum of Lung Cancer Patients and Its Clinical Significance

The application of pleural effusions vascular endothelial growth factor detection in differential diagnosis of patients with benign and malignant diseases

Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients.

Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Serum vascular endothelial growth factor level in patients with lung cancer and breast cancer and its clinical significance

Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis